Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-005-4626-8.

Title:
Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration | Breast Cancer Research and Treatment
Description:
In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Education
  • Science
  • Telecommunications

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 8,123,328 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {πŸ”}

google, scholar, article, pubmed, cancer, cell, breast, growth, insulinlike, kinase, biol, motility, cells, factor, chem, igfi, activated, van, receptor, rho, signaling, human, protein, zhang, yee, activation, gtpases, pathways, factori, golen, access, insulin, jbc, res, privacy, cookies, content, research, downstream, adhesion, rock, science, publish, search, douglas, metastatic, type, response, irs, integrin,

Topics {βœ’οΈ}

cdc42/rac/pak/mkk3/6-mediated pathway month download article/chapter kim el feldman eom sj lee mitogen-activated protein kinase mcp-1-dependent integrin activation receptor-induced cell transformation pak-mediated signaling leads bone-seeking clone exhibits human breast cancer kim hj park stimulated cell motility cell–cell adhesion igf-mediated motility response van golen full metastatic phenotype unique amino-terminal site operable breast cancer vimentin intermediate filaments induced cell motility betapix-enhanced p38 activation human breast tumours inflammatory stimuli biochem rho family gtpases enhances cell motility growth factor receptor focal adhesion kinase full article pdf targeting membrane-localized fak cytokeratin-19-positive cells boettiger ma guvakova focal adhesion plaques multiple signaling pathways minden cj der actin filament disassembly src family kinases minnesota cancer center malignant breast disease small breast carcinomas breast cancer privacy choices/manage cookies cancer cell key molecules downstream han ma sells receptor induces depolarization distinct signaling pathways rat mesangial cells insulin receptor activation cell motility brain-seeking clone

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration
         description:In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.
         datePublished:
         dateModified:
         pageStart:159
         pageEnd:168
         sameAs:https://doi.org/10.1007/s10549-005-4626-8
         keywords:
            breast neoplasms
            cell motility
            focal adhesion kinase
            insulin-like growth factor-I
            mitogen activated protein kinase
            Rho
            type I IGF receptor
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:93
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xihong Zhang
               affiliation:
                     name:University of Minnesota Cancer Center
                     address:
                        name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Min Lin
               affiliation:
                     name:University of Michigan
                     address:
                        name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kenneth L. van Golen
               affiliation:
                     name:University of Michigan
                     address:
                        name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kiyoko Yoshioka
               affiliation:
                     name:Osaka Medical Center for Cancer
                     address:
                        name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kazuyuki Itoh
               affiliation:
                     name:Osaka Medical Center for Cancer
                     address:
                        name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas Yee
               affiliation:
                     name:University of Minnesota Cancer Center
                     address:
                        name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration
      description:In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.
      datePublished:
      dateModified:
      pageStart:159
      pageEnd:168
      sameAs:https://doi.org/10.1007/s10549-005-4626-8
      keywords:
         breast neoplasms
         cell motility
         focal adhesion kinase
         insulin-like growth factor-I
         mitogen activated protein kinase
         Rho
         type I IGF receptor
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:93
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xihong Zhang
            affiliation:
                  name:University of Minnesota Cancer Center
                  address:
                     name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Min Lin
            affiliation:
                  name:University of Michigan
                  address:
                     name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kenneth L. van Golen
            affiliation:
                  name:University of Michigan
                  address:
                     name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kiyoko Yoshioka
            affiliation:
                  name:Osaka Medical Center for Cancer
                  address:
                     name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kazuyuki Itoh
            affiliation:
                  name:Osaka Medical Center for Cancer
                  address:
                     name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas Yee
            affiliation:
                  name:University of Minnesota Cancer Center
                  address:
                     name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:93
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Minnesota Cancer Center
      address:
         name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
         type:PostalAddress
      name:University of Michigan
      address:
         name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
         type:PostalAddress
      name:University of Michigan
      address:
         name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
         type:PostalAddress
      name:Osaka Medical Center for Cancer
      address:
         name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
         type:PostalAddress
      name:Osaka Medical Center for Cancer
      address:
         name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
         type:PostalAddress
      name:University of Minnesota Cancer Center
      address:
         name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xihong Zhang
      affiliation:
            name:University of Minnesota Cancer Center
            address:
               name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Min Lin
      affiliation:
            name:University of Michigan
            address:
               name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
               type:PostalAddress
            type:Organization
      name:Kenneth L. van Golen
      affiliation:
            name:University of Michigan
            address:
               name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
               type:PostalAddress
            type:Organization
      name:Kiyoko Yoshioka
      affiliation:
            name:Osaka Medical Center for Cancer
            address:
               name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Kazuyuki Itoh
      affiliation:
            name:Osaka Medical Center for Cancer
            address:
               name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Douglas Yee
      affiliation:
            name:University of Minnesota Cancer Center
            address:
               name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
      name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
      name:Department of Internal Medicine, University of Michigan, Ann Arbor, USA
      name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
      name:Laboratory of Tumor Biology, Osaka Medical Center for Cancer, Osaka, Japan
      name:Department of Medicine, University of Minnesota Cancer Center, Minneapolis, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(142)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

4.37s.